X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Piramal Healthcare Fact Sheet, Piramal Healthcare Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Piramal Healthcare Fact Sheet   (NCHP)

Here is the latest financial fact sheet of Piramal Healthcare. For more details, see the Piramal Healthcare quarterly results and Piramal Healthcare share price and chart. For a sector overview, read our pharmaceuticals sector report.

PIRAMAL ENTERPRISES Price History

Price Rs 2,778.0
Mkt Cap Rs m 479,372
Vol '000 11.9
P/E X 38.7
P/CF X 42.9
EPS (TTM) Rs 71.7
% ch % -0.7
No. of shares m 172.56
% ch week % -3.3
% ch 1-mth % 4.9
% ch 12-mth % 101.2
52 week H/L Rs 3,083.1/1,377.5
(As on Jun 29, 2017 03:36:00 PM)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

PIRAMAL ENTERPRISES Financials

No. of Mths
Year Ending
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
PIRAMAL ENTERPRISES EQUITY SHARE DATA
High Rs4866256489491,065 
Low Rs341395483522805 
Sales per share (Unadj.) Rs125.1204.0260.9296.9383.0 
Earnings per share (Unadj.) Rs6.5-13.2-29.1165.255.1 
Diluted earnings per shareRs6.5-13.2-29.1165.255.1 
Cash flow per share (Unadj.) Rs14.0-1.0-14.7182.074.1 
Dividends per share (Unadj.) Rs17.5017.5052.5020.0017.50 
Adj. dividends per shareRs17.5017.5052.5020.0017.50 
Dividend yield (eoy) %4.23.49.32.71.9 
Book value per share (Unadj.) Rs651.5621.4540.2680.1719.9 
Adj. book value per shareRs651.5621.4540.2680.1719.9 
Shares outstanding (eoy) m172.56172.56172.56172.56172.56 
Bonus/Rights/Conversions  PI---- 
Price / Sales ratio x3.32.52.22.52.4 
Avg P/E ratio x64.0-38.7-19.54.517.0 
P/CF ratio (eoy) x29.6-496.3-38.34.012.6 
Price / Book Value ratio x0.60.81.01.11.3 
Dividend payout %270.8-132.9-180.712.131.8 
Avg Mkt Cap Rs m71,35487,99797,583126,901161,344 
No. of employees `0002.93.03.02.43.8 
Total wages/salary Rs m4,3647,96511,37012,94816,898 
Avg. sales/employee Rs Th7,411.211,828.614,969.221,167.817,472.6 
Avg. wages/employee Rs Th1,498.22,676.53,779.85,350.24,466.9 
Avg. net profit/employee Rs Th382.8-763.7-1,666.911,776.72,512.8 
PIRAMAL ENTERPRISES INCOME DATA
Net Sales Rs m21,58935,20245,02751,22666,099 
Other income Rs m4,7221,7932,2132,5422,425 
Total revenues Rs m26,31136,99447,24053,76868,524 
Gross profit Rs m-94,3176,3918,85518,723 
Depreciation Rs m1,2932,0962,4692,8993,274 
Interest Rs m2,1555,75010,4965,1069,388 
Profit before tax Rs m1,266-1,736-4,3613,3928,485 
Minority Interest Rs m-38-56-833 
Prior Period Items Rs m0-42-311,5931,593 
Extraordinary Inc (Exp) Rs m-57-1911426,962457 
Tax Rs m562486283,4501,032 
Profit after tax Rs m1,115-2,273-5,01428,5009,506 
Gross profit margin %012.314.217.328.3 
Effective tax rate %4.4-14.3-14.4101.712.2 
Net profit margin %5.2-6.5-11.155.614.4 
PIRAMAL ENTERPRISES BALANCE SHEET DATA
Current assets Rs m16,77440,87642,32449,22047,488 
Current liabilities Rs m25,52081,51593,50852,518104,362 
Net working cap to sales %-40.5-115.4-113.7-6.4-86.0 
Current ratio x0.70.50.50.90.5 
Inventory Days Days7956534841 
Debtors Days Days7462585951 
Net fixed assets Rs m15,01320,76822,58521,03126,532 
Share capital Rs m345345345345345 
"Free" reserves Rs m110,986105,09189,562112,613114,024 
Net worth Rs m112,420107,23693,211117,359124,221 
Long term debt Rs m6,48211,61026,79637,87575,812 
Total assets Rs m147,496202,521215,045209,358308,356 
Interest coverage x1.60.70.61.71.9 
Debt to equity ratio x0.10.10.30.30.6 
Sales to assets ratio x0.10.20.20.20.2 
Return on assets %2.21.72.516.16.1 
Return on equity %1.0-2.1-5.424.37.7 
Return on capital %2.83.15.123.910.0 
Exports to sales %30.222.721.519.517.2 
Imports to sales %13.210.49.38.56.6 
Exports (fob) Rs m6,5157,9879,68710,00911,362 
Imports (cif) Rs m2,8513,6664,2094,3744,364 
Fx inflow Rs m7,0468,89110,51712,01014,435 
Fx outflow Rs m3,4184,3395,0065,7405,183 
Net fx Rs m3,6274,5525,5106,2709,253 
PIRAMAL ENTERPRISES CASH FLOW
From Operations Rs m -6,848 -15,705 -16,044 -22,069 -67,773 
From Investments Rs m -15,818 -16,645 14,829 61,771 -8,768 
From Financial Activity Rs m 6,402 32,807 1,258 -38,646 76,199 
Net Cashflow Rs m -16,264 458 43 1,056 -342 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 52.9%
Foreign collaborators 0.0%
Indian inst/Mut Fund 4.0%
FIIs 26.6%
ADR/GDR 0.0%
Free float 16.5%
Shareholders 93,274
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF Piramal Tower, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400 013
E-MAIL complianceofficer.phl@piramal.com WEB www.piramal.com
TELEPHONE (022) 3046 7839 FAX (022) 3046 7855
SECTOR PHARMACEUTICALS GROUP AJAY PIRAMAL
TR AGENT Link Intime India, C13, Pannalal Silk Mills Compd., LBS Marg, Mumbai-78
AUDITOR Price Waterhouse
CHM: Ajay G. Piramal COMP SEC: Leonard D' Souza YEAR OF INC: 1947 BSE CODE: 500302 FV (Rs): 2 DIV YIELD (%): 0.6

More Pharmaceuticals Company Fact Sheets:   J.B.CHEMICALS  GSK PHARMA  CADILA HEALTHCARE  NOVARTIS  GLENMARK PHARMA  

Compare PIRAMAL ENTERPRISES With:   J.B.CHEMICALS  GSK PHARMA  CADILA HEALTHCARE  NOVARTIS  GLENMARK PHARMA  

Compare PIRAMAL ENTERPRISES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trims Early Gains to Finish Flat; Indigo Slips 2.3%(Closing)

Indian share markets trimmed its early gains in the afternoon session to finish just above the dotted line amid mixed global cues.

Views on news

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

More Views on News

Most Popular

The 'Multibagger IPOs' You Should Be Betting On(The 5 Minute Wrapup)

Jun 22, 2017

Multibagger IPOs are few and far between. Here's how to spot them...

After Farm Loans, Will Govts Waive Off Mudra Loans Next?(Vivek Kaul's Diary)

Jun 19, 2017

If borrowers organise themselves and ask the government to waive off their loans, the government will find it very difficult to say no, having already established a precedent.

Get Ready for Commodity Options!(Daily Profit Hunter)

Jun 16, 2017

Commodity options trading is one step closer to reality. Learn how to take advantage of this tremendous opportunity.

Walter Schloss' Investing Record(Chart Of The Day)

Jun 17, 2017

In a market full of one-hit-wonders, this investor obviously had a formula that worked. And through the think-and-thin of the market.

11 Hidden Costs Associated With Your Home Loan(Outside View)

Jun 16, 2017

Various costs associated with a home loan.

More

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 8-QTR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS